IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Harrow Health, Inc. owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases.
Manufacturing
Pharmaceutical Products
$1.78B
180
SAN DIEGO, Tennessee
Mark L. Baum
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$HROW HARROW, INC. | 61 | 77 | 62 | 73 | 1718.3x | 125.0x | -34.3% | -4.4% | 73.2% | 4.4% | -9.1% | 46.4% | 0.0% | 744.0x | $1.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
HARROW, INC. (HROW) receives a "Hold" rating with a composite score of 61.4/100. It ranks #563 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Mark L. Baum
Chief Executive Officer
Labor Force
180
77
41
52
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for HROW
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for HROW.
View All RatingsYOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Conservative accounting — High cash conversion efficiency
Material decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 77 | 85 | -8DRAG |
| MOMENTUM | 73 | 74 | -1NEUTRAL |
| VALUATION | 62 | 46 | +16ALPHA |
| INVESTMENT | 41 | 74 | -33DRAG |
| STABILITY | 52 | 37 | +15ALPHA |
| SHORT INT | 20 | 5 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 5.4% vs WACC 8.9% (spread -3.5%)
GM 73% vs sector 43%, OM 4% vs sector 1%
Capital turnover 0.26x, R&D intensity 5.0%
Rev growth 46%, 10yr history
Interest coverage 1.1x, Net debt/EBITDA 17.9x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns HARROW, INC. a Hold rating, with a composite score of 61.4/100 and 3 out of 5 stars. Ranked #563 of 7,333 stocks, HROW presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
HROW earns a quality score of 77/100, indicating above-average business quality. The company reports a return on equity of -34.3% (sector avg: -2.5%), gross margins of 73.2% (sector avg: 42.5%), net margins of -9.1% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
HROW's value score of 62/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 1718.33x, an EV/EBITDA of 124.95x, a P/B ratio of 41.28x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 41/100, HROW exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 46.4% vs. a sector average of 5.9% and a return on assets of -4.4% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
HROW shows strong momentum characteristics with a score of 73/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 46.4% year-over-year, while a beta of 1.45 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 52/100, HROW exhibits average financial resilience. Key stability metrics include a beta of 1.45 and a debt-to-equity ratio of 744.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
HARROW, INC.'s short interest score of 20/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.45), elevated leverage (D/E: 744.00x), small-cap liquidity risk. At $1.8B (small-cap), HROW carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
HARROW, INC. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #563 of 7,333 overall (92nd percentile). Key comparisons include ROE of -34.3% trailing the -2.5% sector median and operating margins of 4.4% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HROW currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Quality (77) vs Short Int. (20) — closing this gap could shift the rating.
EV/EBITDA 990% ABOVE SECTOR MEDIAN
ROE 1281% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 72% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate HARROW, INC. (HROW) as a Hold with a composite score of 61.4/100 at a current price of $52.52. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in quality (77th percentile) and momentum (73th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a Narrow Moat rating (41/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
HARROW, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 61.4/100 places it at rank #563 in our full 7,333-stock universe. At $1.8B in market capitalization, HARROW, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 46% and momentum in the 73th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 41th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 73% (+30.7pp vs sector) narrow to operating margins of 4% (+3.1pp vs sector) and net margins of -9.1%, yielding a gross-to-net conversion rate of -12%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $52.52, HARROW, INC. is trading near fair value based on current fundamentals. Our value factor score of 62/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 1718.3x (a 7623% premium to the sector median of 22.3x), EV/EBITDA of 125.0x (at a premium), P/B of 41.3x, P/S of 8.3x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
Gross margins of 73% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 46% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Positive momentum (73th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
A P/E of 1718.3x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
Elevated leverage (744% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
We assign a Very High uncertainty rating to HARROW, INC.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.45), significant leverage (744% debt-to-equity), current negative profitability (net margin -9.1%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.45); significant leverage (744% debt-to-equity); current negative profitability (net margin -9.1%); elevated valuation multiple (P/E 1718.3x) that leaves limited margin for error. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 52th percentile and quality factor at the 77th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 73% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate HARROW, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-34.3%), elevated leverage (744% D/E), negative profitability, weak asset returns (ROA -4.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — HARROW, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, HARROW, INC. receives a Hold rating with a composite score of 61.4/100 (rank #563 of 7,333). Our quantitative framework assigns a Narrow Moat (41/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 61/100.
Our analysis supports a neutral stance on HARROW, INC.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign HARROW, INC. a Narrow Moat rating with a composite moat score of 41/100. The ROIC-WACC spread of -3.5% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that HARROW, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 18.2/20.
The strongest moat sources are growth durability (18.2/20) and margin superiority (16.5/20). Rev growth 46%, 10yr history. GM 73% vs sector 43%, OM 4% vs sector 1%. These pillars form the core of HARROW, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (0.8/20) and reinvestment efficiency (1.8/20). Interest coverage 1.1x, Net debt/EBITDA 17.9x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect HARROW, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 73% providing a solid profitability foundation, robust top-line growth of 46% expanding the revenue base. The margin cascade from 73% gross to 4% operating to -9.1% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 77th percentile.
The margin profile shows gross margins of 73%, operating margins of 4%, net margins of -9.1%. Return metrics include ROE of -34.3% and ROA of -4.4%. Relative to the Manufacturing sector, gross margins are 30.7 percentage points above the sector median of 43%, and ROE of -34.3% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 744%, which may limit financial flexibility, revenue growth of 46%. The sector median D/E is 0%, putting HARROW, INC. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Thin net margins of -9.1% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
High beta of 1.45 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081
U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic TherapiesNASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaP
Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.
As February 2026 begins, U.S. stock markets are experiencing a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, despite recent economic uncertainties such as government shutdowns and trade negotiations. In this invigorated market environment, investors often look for growth companies with high insider ownership as these stocks can indicate confidence from those closest to the company's operations and strategy.